Please note: The information displayed on this page might be outdated.
Triumvira Immunologics: A clinical-stage immunotherapy company intended to develop novel T-cell therapies that are safer and more efficacious than current cell therapy cancer treatments. The company's proprietary technology recruits the entire natural T-cell receptor and functions independent of the Major Histocompatibility Complex (MHC), potentially allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer, thereby providing medical practitioners and patients with new hope to deal with life-threatening diseases.
US - West South Central
Crystal Mountain At Barton Creek
Austin, TX 78733
Austin, TX 78733
Company Participants at Winter Private Company Showcase
Triumvira Immunologics, Vice President, Business Development
Mr. Joshua Carle serves as Vice President of Business Development at Triumvira Immunologics. Mr. Carle is a cross-functional executive with 18 years of strategic transaction and R&D investment experience while in Management Consulting and BioPharma. Mr. Carle has led or advised more than fifty potential strategic transactions, resulting in the successful execution of greater than $2 billion in disclosed deal value and committed R&D funds. Mr. Carle joins from Pfizer Inc., where he drove BD strategy, commercial assessments, and broad transaction support for licensing/M&A efforts for Pfizer Oncology. Previously, Mr. Carle held roles of increasing responsibility in business development activities at Daiichi Sankyo Inc. and Clearview Projects Inc., a strategic advisory firm focused on licensing/M&A for the BioPharma industry. Mr. Carle received his undergraduate degree in Economics from the University of Pennsylvania and MBA from the Villanova School of Business.
Triumvira Immunologics, President & CEO
Paul Lammers, MD, MSc, joined Triumvira Immunologics as President and CEO in January 2018. Before Triumvira, Dr. Lammers served as President & CEO at Mirna Therapeutics, for which company he raised $160 million through venture capital and Federal and State government funding, as well as a public listing on NASDAQ. Previously, he served as Chief Medical Officer and Head of US Product Development for EMD Serono. During his early industry tenure, Dr. Lammers also held various executive/senior management positions in clinical development, medical and regulatory affairs, at different pharmaceutical companies, as well as at small public and privately held biotech companies. Dr. Lammers serves as Lead Independent Director for publicly-traded Salarius Pharmaceuticals, and as Director for private biotech company, Immunomet.